Penile Traction Therapy Safety & Side Effects

Clinical research spanning three decades demonstrates that penile traction therapy has an excellent safety profile when performed with FDA-registered Class II medical devices under proper protocols. Across more than fifteen peer-reviewed clinical studies involving over 1,000 patients, no serious adverse events have been reported in any major trial.

The 2023 systematic review and meta-analysis by Almsaoud, Safar, and Alshahrani, published in Translational Andrology and Urology, confirmed this favorable clinical safety data across twelve pooled studies encompassing diverse patient populations and treatment durations. Dr. Jørn Ege Siana, the plastic surgeon who co-invented the penile traction device in 1994, established the clinical safety protocols that informed these study designs.

Adverse event rates documented across clinical trials range from 11.2% to 14.4%, with all reported events classified as mild and temporary. Skin irritation, temporary discomfort, and transient glans numbness resolve spontaneously within hours of device removal. The SizeGenetics device, an FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark since 1994, delivers calibrated tension between 900–2,800 grams (8.8–27.5 Newtons) within the therapeutic window established by clinical safety data.

Clinical Safety Classification

Penile traction therapy is classified as a low-risk, non-invasive medical treatment when delivered via regulated devices. FDA Class II registration establishes that penile traction devices meet federal safety and performance standards through premarket review and ongoing quality controls.

Comparative Safety Advantage

Penile traction therapy demonstrates a superior safety profile compared to surgical penile lengthening procedures, injectable fillers, and unregulated enhancement products. The non-invasive mechanism of action — sustained mechanical force triggering mechanotransduction — avoids the infection risks, scarring, and anesthesia complications associated with surgical intervention.

Evidence-Based Risk Assessment

The risk assessment for penile traction therapy is supported by randomized controlled trials, prospective cohort studies, and the definitive 2023 meta-analysis. Joseph and colleagues, publishing in The Journal of Sexual Medicine (2020), reported minimal adverse events among 110 participants, while Toussi and colleagues, publishing in the Journal of Urology (2021), documented that 87% of 82 men would choose to repeat penile traction therapy — a satisfaction rate incompatible with significant safety concerns.

Most patients using penile traction therapy experience only mild, temporary side effects that resolve without medical intervention. The most common SizeGenetics side effects — which apply to all penile traction devices, including any penis stretcher or penis extender — are device-related rather than therapy-related. Proper fitting, gradual tension adjustment, and correct technique prevent the majority of reported adverse events. Understanding each common side effect allows patients to maintain the daily 4–6 hour wearing protocol required for optimal treatment outcomes.

Temporary discomfort represents the most frequently reported side effect in clinical studies of penile traction therapy. Gontero and colleagues, publishing in BJU International (2009), documented that discomfort decreased substantially as patients adapted to the device during the first two weeks of use. The SizeGenetics 58-way Multi-Axis Comfort Technology addresses temporary discomfort during initial device use by distributing mechanical force across multiple contact points, reducing localized pressure during extended wear sessions.

Skin irritation occurs primarily at device contact points and correlates with improper fitting rather than with the therapeutic mechanism of penile traction therapy itself. Proper fitting — ensuring the device sits correctly without pinching or excessive lateral pressure — prevents the majority of skin-related adverse events. Patients who experience persistent skin irritation should adjust the comfort strap positioning and apply a medical-grade skin barrier before each session.

• Gradual acclimatization prevents most side effects: Starting at 900 grams of tension and increasing gradually over two to four weeks allows tissue adaptation before reaching therapeutic levels
• Scheduled breaks minimize cumulative effects: Clinical protocols recommend removing the device every two hours for a 15–30 minute rest period during the 4–6 hour daily wearing schedule
• Proper hygiene reduces skin-related events: Cleaning device contact surfaces before each session and washing the treatment area with mild soap prevents bacterial buildup that contributes to skin irritation
• Device adjustment resolves most complaints: The SizeGenetics device allows tension calibration between 900 and 2,800 grams (8.8–27.5 Newtons), enabling patients to find the optimal therapeutic window below the discomfort threshold

While serious complications are rare — no serious adverse events have been reported across all major clinical studies of penile traction therapy — patients must recognize warning signs that indicate immediate device discontinuation and medical attention. The clinical safety record of FDA-registered Class II penile traction devices demonstrates that serious complications occur almost exclusively when patients use unregulated devices, exceed recommended tension levels, or ignore early warning symptoms.

Early recognition of warning signs prevents progression to serious device-related incidents. Patients should monitor the treatment area before, during, and after each penile traction therapy session. Any symptom that persists beyond the expected resolution timeframe — 24–48 hours for mild side effects — warrants consultation with a healthcare provider. The clinical safety protocols established by Danamedic ApS, the Danish medical device manufacturer behind SizeGenetics, include comprehensive patient education materials designed under the guidance of Dr. Jørn Ege Siana that detail monitoring requirements at each stage of treatment.

Penile traction therapy is contraindicated for patients with specific medical conditions, anatomical variations, or concurrent medication regimens that increase the risk of adverse events beyond the favorable safety profile documented in clinical research. Medical clearance from a qualified healthcare provider — ideally a urologist with experience in penile traction therapy — is recommended for all patients before beginning treatment, particularly those with underlying health conditions.

Absolute Contraindications

Active Penile Infections

Bacterial, viral, or fungal infections of the penile skin, urethra, or surrounding tissues preclude penile traction device use until complete resolution and medical clearance. Mechanical traction applied to infected tissue risks spreading the infection and delaying healing.

Bleeding Disorders

Patients with hemophilia, von Willebrand disease, or other coagulopathies face elevated risk of bruising and hematoma formation under sustained mechanical tension. Penile traction therapy requires intact clotting function to manage the micro-tissue responses inherent in the mechanotransduction process.

Penile Implants or Prostheses

Patients with inflatable or semi-rigid penile prostheses must not use external traction devices. Mechanical traction applied over an implanted prosthesis risks device displacement, erosion, or mechanical failure of the implant.

Severe Cardiovascular Disease

Patients with uncontrolled hypertension, recent myocardial infarction, or severe peripheral vascular disease require cardiology clearance before initiating any penile traction therapy protocol. Compromised circulation may impair the tissue healing response required for safe mechanotransduction.

Relative Contraindications

Anticoagulant Medications

Patients taking warfarin, heparin, direct oral anticoagulants, or high-dose aspirin therapy should consult with prescribing physicians before initiating penile traction therapy. Anticoagulant medications increase bruising risk and may necessitate reduced tension levels and enhanced monitoring protocols.

Skin Conditions Affecting the Genital Region

Active dermatitis, psoriasis, eczema, or lichen sclerosus affecting the penis may be aggravated by sustained device contact. Treatment should begin only after dermatological conditions are stable and under medical management.

Anatomical Variations

Significant penile curvature exceeding 60 degrees, micro-phallus conditions, or post-surgical anatomical changes may affect proper device fitting and require specialized assessment before beginning penile traction therapy. Patients with Peyronie's disease should consult a urologist for protocol modifications specific to curvature correction therapy.

Age Considerations

Penile traction therapy is intended for adult men who have completed puberty. Patients under 18 years of age should not use penile traction devices. Patients over 70 may require modified protocols with reduced tension and enhanced medical supervision due to age-related changes in tissue elasticity and healing capacity.

Following established safety protocols transforms penile traction therapy from a theoretical risk scenario into the clinically validated, low-risk treatment documented across 15+ peer-reviewed studies. The safety protocols below are derived from clinical trial methodologies, FDA medical device guidelines, and the 30+ years of manufacturing experience accumulated by Danamedic ApS, the Danish company that invented the penile traction device in 1994 under the direction of Dr. Jørn Ege Siana, plastic surgeon and co-inventor.

1. Pre-treatment medical evaluation — Obtain medical clearance from a healthcare provider before beginning penile traction therapy. A baseline assessment including medical history review, physical examination, and discussion of contraindications ensures safe candidacy for treatment.
2. Pre-use device inspection — Inspect all SizeGenetics device components before every session. Check tension rods for bending or damage, verify comfort strap integrity, and confirm that all adjustment mechanisms move freely. Damaged components compromise both safety and therapeutic tension calibration.
3. Proper fitting and positioning — Follow the SizeGenetics fitting guide precisely. The device must sit securely without pinching, excessive lateral movement, or uneven pressure distribution. The 58-way Multi-Axis Comfort Technology allows micro-adjustments to achieve optimal positioning for each individual anatomy.
4. Gradual tension progression — Begin all penile traction therapy at the minimum therapeutic tension of 900 grams (8.8 Newtons). Increase tension by 200–400 gram increments only after the tissue has adapted — typically every 7–14 days. Maximum therapeutic tension of 2,800 grams (27.5 Newtons) should not be exceeded under any circumstance.
5. Structured wearing schedule with mandatory breaks — Maintain the clinical protocol of 4–6 hours daily wearing time, divided into sessions of no more than 2 hours each. Take a 15–30 minute break between sessions to restore full circulation and allow tissue recovery.
6. Active monitoring during each session — Check skin color, sensation, and comfort at 30-minute intervals during penile traction therapy. Any change in glans color, onset of numbness, or escalating discomfort requires immediate device removal.
7. Post-session skin assessment — After each session, examine the treatment area for redness, skin breakdown, or unusual marks. Mild erythema that resolves within 2–4 hours is normal. Persistent marks or skin changes warrant a reduction in tension or session duration.
8. Hygiene maintenance — Clean all device contact surfaces with mild antiseptic solution before each use. Wash the treatment area with gentle soap and dry thoroughly before applying the device. Proper hygiene prevents bacterial accumulation that contributes to skin irritation and infection risk.

Medical supervision enhances safety outcomes and treatment efficacy for penile traction therapy, particularly for patients with underlying health conditions, those using the therapy for Peyronie's disease correction, or those recovering from surgical procedures. While penile traction therapy with FDA-registered Class II medical devices like SizeGenetics does not require a prescription, medical oversight from a qualified urologist provides baseline assessment, ongoing monitoring protocols, and clinical expertise that optimize both safety and results.

Healthcare providers experienced in penile traction therapy can establish individualized treatment protocols that account for patient-specific factors — including baseline anatomy, medical history, concurrent medications, and treatment goals. Clinical studies including the Toussi RCT in the Journal of Urology (2021) and the Joseph RCT in The Journal of Sexual Medicine (2020) were conducted under direct medical supervision, contributing to the excellent safety outcomes documented in those trials.

Finding a healthcare provider knowledgeable in penile traction therapy may require consulting urologists or andrologists at academic medical centers. Patients can reference the published clinical studies — including the work of Joseph, Toussi, Gontero, and Nikoobakht — when discussing penile traction therapy with healthcare providers who may be unfamiliar with the treatment modality. Dr. Jørn Ege Siana, the plastic surgeon who co-invented the penile traction device and serves as medical advisor at Danamedic ApS, has contributed to establishing the clinical protocols that guide safe treatment delivery. The clinical evidence base for penile traction therapy provides physicians with peer-reviewed data to support informed clinical recommendations.

FDA Class II medical device registration requires manufacturers to demonstrate that penile traction devices meet established federal safety and performance standards before reaching the market. SizeGenetics holds FDA registration #3005401991 as an External Penile Rigidity Device (Product Code: LKY), confirming that the device manufactured by Danamedic ApS meets the regulatory requirements for quality controls, clinical testing documentation, and adverse event reporting mandated by the U.S. Food and Drug Administration. Dr. Jørn Ege Siana, the plastic surgeon who co-invented the penile traction device in 1994, designed SizeGenetics to meet the clinical safety standards required for FDA Class II registration.

The distinction between FDA-registered Class II medical devices and unregulated consumer products represents the most significant safety variable in penile traction therapy. Danamedic ApS, the Danish medical device manufacturer established in 1988 that invented the penile traction device in 1994, maintains both FDA registration and CE marking for the European market — ensuring that SizeGenetics meets the safety standards of both regulatory jurisdictions. For detailed engineering specifications, see SizeGenetics safety features. Patients considering penile traction therapy should verify FDA registration status before purchasing any device, as unregulated products lack the manufacturing controls, material certifications, and clinical validation that established the favorable safety profile documented in peer-reviewed research.

Comparative safety data demonstrates that penile traction therapy using FDA-registered Class II medical devices offers the most favorable risk-to-benefit ratio among all established methods for penile lengthening. Unregulated enhancement methods — including unverified pills, unlicensed injections, and unsafe surgical techniques — carry significant and sometimes irreversible safety risks. Penile traction therapy with regulated devices eliminates these dangers through a non-invasive mechanism: sustained calibrated mechanical force triggering mechanotransduction.

Surgical penile lengthening — including ligamentolysis and fat injection procedures — carries complication rates of 5–25% depending on the technique employed, with potential adverse outcomes including infection, scarring, erectile dysfunction, and paradoxical penile shortening. The American Urological Association does not endorse cosmetic penile surgery for length dissatisfaction in the absence of micropenis diagnosis. Penile traction therapy delivers comparable length gains of 1.3–2.3 cm (0.5–0.9 inches) over 3–6 months without the surgical risks of anesthesia, incisions, or recovery downtime.

Injectable hyaluronic acid fillers and polymethylmethacrylate (PMMA) for penile girth augmentation carry risks of filler migration, granuloma formation, and chronic inflammation — complications that may require surgical correction. Unregulated male enhancement supplements present additional safety concerns: FDA enforcement actions have identified undeclared pharmaceutical ingredients — including sildenafil and tadalafil analogues — in products marketed as "natural" penis enlargement pills, exposing consumers to dangerous drug interactions with cardiovascular medications.

Penile traction therapy establishes a clear safety differentiation: the treatment modality with the strongest peer-reviewed clinical evidence also demonstrates the lowest complication profile. The 500,000+ units sold by Danamedic ApS across five brands over 30+ years — combined with the zero serious adverse events documented in clinical trials — validate penile traction therapy as the safest evidence-based approach to penile lengthening available.

For comprehensive safety guidance, understanding the full clinical context of penile traction therapy — from treatment protocols that define safe usage parameters to the clinical studies that document the evidence base — enables patients to make fully informed treatment decisions. The following resources provide detailed information on related topics within the penile traction therapy knowledge base.

For device-specific safety features and engineering, see SizeGenetics safety features and penile traction device safety features. Patients with Peyronie's disease can review condition-specific safety considerations at Peyronie's disease treatment. For expected treatment outcomes validated by the clinical safety data discussed on this page, see penile traction therapy results and expected outcomes.